Ticker
ACAD

Price
22.29
Stock movement up
+0.30 (1.36%)
Company name
ACADIA Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
3.62B
Ent value
3.69B
Price/Sales
6.99
Price/Book
9.03
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
445.80
PEG
-
EPS growth
-
1 year return
48.20%
3 year return
-25.34%
5 year return
4.09%
10 year return
0.58%
Last updated: 2023-11-24
Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
November 6, 2023

iO Charts is a Seeking Alpha partner

ACADIA Pharmaceuticals Inc. (NASDAQ:NASDAQ:ACAD) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ETCompany ParticipantsJessica Tieszen - Associate...
November 3, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ACAD does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales6.99
Price to Book9.03
EV to Sales7.13
Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
November 2, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
November 1, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count162.23M
EPS (TTM)-1.34
FCF per share (TTM)-0.71

Income statement

Loading...
Income statement data
Revenue (TTM)517.24M
Gross profit (TTM)507.07M
Operating income (TTM)-223.60M
Net income (TTM)-215.97M
EPS (TTM)-1.34
EPS (1y forward)0.05

Margins

Loading...
Margins data
Gross margin (TTM)98.03%
Operating margin (TTM)-43.23%
Profit margin (TTM)-41.76%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash114.85M
Net receivables63.08M
Total current assets507.94M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets587.81M
Accounts payable12.75M
Short/Current long term debt52.70M
Total current liabilities125.63M
Total liabilities187.40M
Shareholder's equity400.41M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-114.03M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-114.03M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-53.94%
Return on Assets-36.74%
Return on Invested Capital-53.94%
Cash Return on Invested Capital-28.48%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open22.02
Daily high22.30
Daily low21.86
Daily Volume529K
All-time high57.00
1y analyst estimate22.50
Beta0.58
EPS (TTM)-1.34
Dividend per share-
Ex-div date-
Next earnings date26 Feb 2024

Downside potential

Loading...
Downside potential data
ACADS&P500
Current price drop from All-time high-60.89%-4.69%
Highest price drop-96.29%-56.47%
Date of highest drop12 Nov 20109 Mar 2009
Avg drop from high-48.39%-11.47%
Avg time to new high53 days13 days
Max time to new high1820 days1805 days
Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
September 28, 2023

iO Charts is a Seeking Alpha partner

Acadia Pharmaceuticals' gains recently disappeared despite the strong launch of Daybue. Learn why I rate ACAD stock a buy.
September 26, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ACAD (ACADIA Pharmaceuticals Inc) company logo
Marketcap
3.62B
Marketcap category
Mid-cap
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Employees
511
Investor relations
-
SEC filings
CEO
Stephen R. Davis
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
ACADIA's shift to net positive income is driven by Daybue's successful Q2 debut and increased Nuplazid sales. See why ACAD presents a compelling investment opportunity.
September 23, 2023

iO Charts is a Seeking Alpha partner

ACADIA Pharmaceuticals Inc. (NASDAQ:NASDAQ:ACAD) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ETCompany ParticipantsJessica Tieszen - Associate...
August 3, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
The following slide deck was published by ACADIA Pharmaceuticals Inc.
August 3, 2023
Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
August 2, 2023
Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
August 1, 2023
Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
July 14, 2023
Acadia Pharmaceuticals' stock rose 20% after expanding rights to Rett syndrome drug Daybue, with projected increased sales for Q2 and Q3 2023. Read more here.
July 14, 2023
Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
July 13, 2023
Get the latest news and real-time alerts from ACADIA Pharmaceuticals Inc. (ACAD) stock at Seeking Alpha.
June 13, 2023
Acadia's Q1 2023 financials demonstrate marginal improvement when compared to the same period in 2022. Find out why I am bearish on ACAD stock.
May 9, 2023
ACADIA Pharmaceuticals Inc. (NASDAQ:NASDAQ:ACAD) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ETCompany ParticipantsMark Johnson - Vice President of...
May 9, 2023
The following slide deck was published by ACADIA Pharmaceuticals Inc.
May 8, 2023
iO Charts is a Seeking Alpha partnerNext page